Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

Exclusion Criteria

• •Patients with PH1 that are not satisfactorily treated with current standard of care; i.e., 24-hour urinary oxalate (Uox) excretion ≥ 0.7 (millimoles) mmol for participants 18 years and older, or greater or lesser than (≥) 0.7 mmol per 1.73 metre square (m\^2) body surface area (BSA) for participants less than 18 years of age
• •Estimated GFR at screening ≥ 30 millilitres per minute (mL/min) normalized to 1.73 m\^2 BSA
• •No renal or hepatic transplantation; prior or planned within the treatment period
• •No documented evidence of clinical manifestations of systemic oxalosis (including pre existing retinal, heart, or skin calcifications, or history of severe bone pain, pathological fractures, or bone deformations)
• •Patient not currently on dialysis
• •Plasma oxalate ≤ 30 micromoles per litre (μmol/L)
• •Female patients not breastfeeding or pregnant
• •The potential benefit for the individual patient justifies the potential risks of treatment as per prescribing physician judgment